MTOR and melanoma: Original research by Sweetlove et al. investigated the effects of a MEK inhibitor (selumetinib)and a BRAF inhibitor (vemurafenib) alone and in combination with inhibitors of pan-PI3K (ZSTK474), pan-PI3K/mTOR (BEZ235), individual PI3K isoforms (p110α, A66; p110β, TGX-221; p110γ, AS-252424; p110δ, idelalisib), or mTORC1/2 (KU-0063794) on nine metastatic BRAF-mutated melanoma cell lines.